Follicular Lymphoma (FL)

Oncology
4
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
4
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
250%
Cell Therapy
125%
Small Molecule
125%

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
2 programs
2
OdronextamabPhase 3Monoclonal Antibody1 trial
OdronextamabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06091254Recruiting822Est. Nov 2029
NCT06097364Active Not Recruiting733Est. Jul 2029
Novartis
NovartisBASEL, Switzerland
1 program
1
TisagenlecleucelPhase 3Cell Therapy1 trial
Active Trials
NCT05888493Active Not Recruiting109Est. Jan 2031
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
1
ZandelisibPhase 3Small Molecule1 trial
Active Trials
NCT04745832Terminated82Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
RegeneronOdronextamab
RegeneronOdronextamab
NovartisTisagenlecleucel
Kyowa Hakko KirinZandelisib

Clinical Trials (4)

Total enrollment: 1,746 patients across 4 trials

NCT06091254RegeneronOdronextamab

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Start: Dec 2023Est. completion: Nov 2029822 patients
Phase 3Recruiting
NCT06097364RegeneronOdronextamab

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Start: Nov 2023Est. completion: Jul 2029733 patients
Phase 3Active Not Recruiting
NCT05888493NovartisTisagenlecleucel

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Start: Oct 2023Est. completion: Jan 2031109 patients
Phase 3Active Not Recruiting
NCT04745832Kyowa Hakko KirinZandelisib

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Start: Aug 2021Est. completion: Mar 202382 patients
Phase 3Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
2h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
2h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
2h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,746 patients
Monoclonal Antibody is the dominant modality (50% of programs)
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)